Rigel Pharmaceuticals released the final data from its Phase 1/2 ARROW study of GAVRETO (pralsetinib) in the Journal of Clinical Oncology on March 31 2026. The publication presents 42 months of follow‑up and confirms durable responses and a manageable safety profile in patients with metastatic RET‑fusion‑positive non‑small cell lung cancer (NSCLC). The data reinforce GAVRETO’s position as a once‑daily, oral RET inhibitor and support its use as a first‑line treatment option for this rare patient population.
The 42‑month analysis shows sustained objective response rates and progression‑free survival that exceed expectations for this patient group, while the safety profile remains consistent with earlier reports. The robust evidence strengthens the case for label expansion and positions Rigel to pursue additional regulatory filings for RET‑positive NSCLC, potentially expanding the drug’s commercial reach beyond its current indications.
Rigel’s Q4 2025 results underscore the commercial momentum behind GAVRETO. Total revenue rose to $69.8 million, driven by a 41% year‑over‑year increase in net product sales of $65.4 million. Full‑year 2025 revenue reached $294.3 million, up 60% from 2024, with net product sales of $232.0 million. For 2026, Rigel is guiding total revenue of $275–$290 million, a slight decline from the previous year, largely due to an anticipated drop in contract revenue. Net product sales guidance of $255–$265 million, however, remains on an upward trajectory, reflecting continued growth in core product lines.
President and CEO Raul Rodriguez highlighted the strong commercial execution of 2025, noting record net product sales and $77 million in cash generation. He added that in 2026 the company will “continue to execute across all areas of the business—driving sustained commercial performance, supporting our expanding clinical programs with a solid financial foundation, delivering preliminary results from the dose‑expansion phase of our R289 study, and exploring opportunities to add new products to our portfolio.” Chief Medical Officer Lisa Rojkjaer emphasized that the long‑term data “further support pralsetinib’s role as a first‑line treatment option for RET‑fusion‑positive NSCLC patients.”
Market reaction to the earnings release was muted. Investors focused on the projected revenue decline for 2026, driven by a significant expected drop in contract revenue, and the large non‑cash deferred tax benefit that complicated earnings comparisons. Despite the strong clinical data, the guidance signals a cautious outlook for the near term, tempering enthusiasm among market participants.
The publication of the final ARROW data solidifies GAVRETO’s therapeutic value and provides a foundation for future regulatory submissions. Coupled with the company’s ongoing R289 program in lower‑risk MDS and a strategic focus on hematology and oncology, Rigel is positioning itself to expand its portfolio while maintaining a disciplined commercial approach. The combination of robust clinical evidence, solid financial performance, and a clear growth strategy underscores the company’s commitment to delivering value to patients and investors alike.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.